A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy

Click to increase image sizeClick to decrease image size

Author contributions

Contribution: K.N., T.S., M.S, S.R., M.R., S.M collected and analyzed the data; K.N., A.D., M.R., S.M., contributed to data interpretation; M.H., N.K., U.A.S., C.T., D.J.C, O.B.L., H.H., A.M.L., H.L., G.S., M.S., S.G., S.Z., O.L., S.M. provided patients and contributed to data interpretation; S.M., designed the project and contributed to patient samples and data analysis and interpretation; and all authors were involved in writing the manuscript.

Disclosure statement

Karthik Nath: Memorial Sloan Kettering Core Grant P30 CA008748. Megan Salcedo: Memorial Sloan Kettering Core Grant P30 CA008748. Malin Hulcrantz: Grants: Memorial Sloan Kettering Core Grant P30 CA008748, Swedish Blood Cancer Foundation, the Karolinska Institute Foundations, GSK, Amgen, and Daiichi Sankyo; serves in Scientific advisory committee: GSK, and Consultancy: Curio Science LLC, Intellisphere LLC. Neha Korde: Grants: Memorial Sloan Kettering Core Grant P30 CA008748, Amgen, Janssen; Honoraria: Medimmune; Consulting: CCO, PER. Urvi A. Shah: Grant/grants pending: Memorial Sloan Kettering Core Grant P30 CA008748, Parker Institute of Cancer Immunotherapy, International Myeloma Society, Paula and Rodger Riney Foundation, Allen Foundation Inc, Janssen, Celgene/BMS, MSK Paul Calabresi Career Development Award for Clinical Oncology K12CA184746; Payment for lectures including service on speaker bureaus: ACCC, MJH Life Sciences. Carlyn Tan: Grant: Memorial Sloan Kettering Core Grant P30 CA008748, Consulting fee: Janssen. David J Chung: Grant, Memorial Sloan Kettering Core Grant P30 CA008748. Oscar B. Lahoud: Grant, Memorial Sloan Kettering Core Grant P30 CA008748, Advisory Boards for MorphoSys. Hani Hassoun: Grants, Memorial Sloan Kettering Core Grant P30 CA008748, Janssen and Nerviano. Alexander M. Lesokhin: Grant: Memorial Sloan Kettering Core Grant P30 CA008748, Genmab, Amgen, Bristol-Myers Squibb, and Janssen; has served on an advisory panel for Trillium Therapeutics, Pfizer, and Bristol-Myers Squibb; Has received research funding from Janssen Oncology, Trillium Therapeutics, Genentech, Bristol-Myers Squibb, Sanofi, Pfizer Cancer Network, Patents/Royalties: Serametrix, Inc. Heather J. Landau: Grant: Memorial Sloan Kettering Core Grant P30 CA008748, Consultancy: Karyopharm, Pfizer, Inc., Celgene, Juno, Clinical Care Options, Prothena, Caelum Biosciences, Takeda, Janssen. Grants/grants pending: Caelum Biosciences, Inc. Takeda Pharmaceuticals, Janssen Scientific Affairs, LLC. Gunjan Shah: Grant: Memorial Sloan Kettering Core Grant P30 CA008748. Research Funding: Janssen, Amgen, Beyond Spring. Michael Scordo: Grant: Memorial Sloan Kettering Core Grant P30 CA008748. Consultancy; McKinsey and Company (past), Angiocrine Bioscience Inc (past), Omeros Corporation, Kite – A Gilead Company. Educational presentations; i3Health, Medscape. Sergio A Giralt: Grant: Memorial Sloan Kettering Core Grant P30 CA008748, Miltenyi Biotec, Takeda Pharmaceutical Co., Celgene Corp., Amgen Inc., Sanofi, Johnson and Johnson, Inc., Actinium Pharmaceuticals, Inc., Amgen, Actinum, Celgene, Johnson and Johnson, Miltenyi, Takeda, Omeros. Board Membership: Kite Pharmaceuticals, Inc., Celgene Corp., Sanofi, Novartis, Johnson and Johnson, Inc., Amgen Inc., Takeda Pharmaceutical Co., Jazz Pharmaceuticals, Inc., Actinium Pharmaceuticals, Inc. Consultancy: Amgen, Celgene, Actinuum, Johnson and Johnson, Janssen, Jazz Pharmaceuticals, Takeda, Novartis, Kite, Spectrum Pharma. Saad Z. Usmani: Grant/Personal Fees: Memorial Sloan Kettering Core Grant P30 CA008748, Amgen, Abbvie, BMS, Celgene, Pharmacyclics, Sanofi, Seattle Genetics, MundiPharma, Janssen, Takeda, Skyline DX, Merck. GSK, Gilead, Genentech, Oncopeptides. Mikhail Roshal: Grant: Memorial Sloan Kettering Core Grant P30 CA008748. Board Membership: Auron Pharma. Grants/grants pending: Roche, NGM, Beat AML. Stock/stock options: Auron Pharma. Ola Landgren: Grant: National Institutes of Health, the National Cancer Institute, the US Food and Drug Administration, the Multiple Myeloma Research Foundation, the International Myeloma Foundation, the Leukemia and Lymphoma Society, the Perelman Family Foundation, the Rising Tide Foundation, Amgen, Celgene, Janssen, Takeda, Glenmark, Seattle Genetics, and Karyopharm, Memorial Sloan Kettering Core Grant (P30 CA008748). Advisory boards for Adaptive, Amgen, Binding Site, Bristol Myers Squibb, Celgene, Cellectis, Glenmark, Janssen, Juno, and Pfizer; and serving on Takeda, Merck, Janssen, and Theradex independent data monitoring committees outside the submitted work. Sham Mailankody: Grants: Memorial Sloan Kettering Core Grant (P30 CA008748), Allogene Therapeutics, Takeda Oncology, Juno Therapeutics, Bristol Myers Squibb, Janssen Oncology, Fate Therapeutics; has served on an advisory panel for Legend Biotech, Evicore, Janssen Oncology, BioAscend; Has received honoraria from Plexus Communication, OncLive, Physician Education Resource.

Additional information

Funding

This work was supported by Janssen Pharmaceuticals.